Renewable bioproducts company Solazyme announces global launch of Firming & Lifting skincare, adding to its Algenist line of products made from microalgae

Alison Gallant

SOUTH SAN FRANCISCO, California , January 10, 2012 (press release) – The Algenist Firming & Lifting line combines Solazyme’s anti-aging ingredient, Alguronic Acid®, with an active blend of proteins and peptides in three new products to firm and tone the skin

Solazyme, Inc. (NASDAQ: SZYM - News), a renewable oil and bioproducts company, today announced the addition of the Firming & Lifting skincare line to their luxury skincare brand, Algenist. The line will be initially distributed in over 1,100 retail locations worldwide including over 300 Sephora® US and Canada stores, 580 Sephora EMEA locations, 308 Sephora inside JCPenney stores, and on QVC starting January 2012. It will feature three new products targeted at women ages 45-60 looking to repair and restructure the skin and will retail for under $94 USD

The line combines for the first time Solazyme’s breakthrough anti-aging ingredient, Alguronic Acid, with ProPeptide3, a unique blend of active proteins and peptides. Powered by the exclusive and powerful Alguronic Acid + ProPeptide3 skin restructuring complex, clinical studies have shown Algenist Firming & Lifting skincare products to enhance skin firmness, tone and elasticity.

The Firming & Lifting line will launch with three revolutionary skincare products. The Firming & Lifting Cream ($94), made with a blend of avocado, olive fruit oils and alguronic acid, is clinically measured to increase firmness and elasticity in just ten days. The Firming & Lifting Eye Gel ($68), made with alfalfa seed extract, caffeine and alguronic acid, is packed with active proteins and peptides to visibly firm and lift the delicate skin around the eyes. Finally, the Firming & Lifting Intensive Mask ($52) contains jojoba, green tea, vitamin A and alguronic acid, where studies have shown immediate firming, toning, and tightening effects.

“Algenist has celebrated remarkable success both in the U.S. and internationally with our initial introduction of Alguronic Acid,” said Frederic Stoeckel, Senior Vice President & General Manager, Solazyme Health Sciences. “Combining the same proven capabilities of biotechnology and microalgae, the Algenist Firming & Lifting line is intended to reach an entirely new demographic of customers looking for innovative skincare solutions to strengthen and repair the skin. We are proud of the caliber of visionary beauty retailers that have joined forces to launch our new Firming & Lifting line and we look forward to further bringing cutting-edge technology to the forefront of the beauty industry.”

In March of 2011, Solazyme successfully launched the initial Algenist product portfolio worldwide, immediately emerging as a world-wide phenomenon and has maintained strong sales results to date. Algenist was the world’s first skincare line to introduce the never-before-seen anti-aging ingredient, Alguronic Acid, to the market. In clinical trials, Alguronic Acid demonstrated superior anti-aging benefits and outperformed a multitude of highly successful regenerative compounds, including hyaluronic acid and retinol.

In addition to the initial January launch, the Algenist Firming & Lifting line will expand to the United Kingdom beginning March 2012 in all Space NK stores.

About Solazyme, Inc.

Solazyme, Inc. (NASDAQ: SZYM - News) is a renewable oil and bioproducts company that transforms a range of low-cost plant-based sugars into high-value oils. Headquartered in South San Francisco, Solazyme’s renewable products can replace or enhance oils derived from the world’s three existing sources – petroleum, plants and animal fats. Initially, Solazyme is focused on commercializing its products into three target markets: (1) fuels and chemicals, (2) nutrition and (3) skin and personal care.

Solazyme®, the Solazyme logo and other trademarks or service names are trademarks of Solazyme, Inc.

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements concerning (1) the timing of future product launches and the number of stores in which the products will be launched and (2) the results that may be achieved by using our products. Any such statement may be influenced by a variety of factors, many of which are beyond the control of Solazyme, that could cause actual outcomes and results to be materially different from those projected, described or implied in this press release. Potential risks and uncertainties include, among others, changing priorities of our distribution partners and other risks detailed in the "Risk Factors" sections of our quarterly reports on Form 10-Q filed with the Securities and Exchange Commission. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. Solazyme is not under any duty to update any of the information in this press release.

© 2024 Business Wire, Inc., All rights reserved.